Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
cobas EGFR mutation test v2
epidermal growth factor receptor gene (EGFR) mutation
next-generation sequencing
non-small cell lung cancer
oncomine dx target test
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
22
09
2022
received:
16
08
2022
accepted:
23
09
2022
pubmed:
7
10
2022
medline:
18
11
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
As the number of genetic mutations that must be tested increases, the Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer-related genes is becoming the main test used in preference to single-molecule testing. In this study, we evaluated the performance of ODxTT and cobas EGFR mutation test v2 (cobas EGFR), one of the single-molecule tests, in detecting EGFR mutations. Samples from 211 patients diagnosed with NS-NSCLC were tested simultaneously or sequentially with the cobas EGFR mutation test and ODxTT. We compared the success and detection rates of both tests and evaluated their equivalence by determining the concordance rate and k-coefficient of both tests. The success rate in detecting EGFR mutations was 95.7% for ODxTT and 100% for cobas EGFR. EGFR mutations were detected in 26.5% of samples with ODxTT and in 28.0% with cobas EGFR. For the 200 samples successfully analyzed with both tests, the concordance rate and k-coefficient were 97.5% and 0.938, respectively. ODxTT failed to detect two exon 19 deletion mutations (p.E746_P753delinsVS and p.E746_P753delinsLS), and cobas EGFR failed to detect three instances of an exon 19 deletion (p.L747_P753delinsS), L861R, and an exon 20 insertion. The success rate of ODxTT is slightly inferior to that of cobas EGFR. ODxTT shared a high concordance rate and k-coefficient with cobas EGFR in detecting EGFR mutations, but discordant results between the two tests were observed in a few cases, mainly due to the difference of detectable EGFR variants.
Sections du résumé
BACKGROUND
As the number of genetic mutations that must be tested increases, the Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer-related genes is becoming the main test used in preference to single-molecule testing. In this study, we evaluated the performance of ODxTT and cobas EGFR mutation test v2 (cobas EGFR), one of the single-molecule tests, in detecting EGFR mutations.
METHODS
Samples from 211 patients diagnosed with NS-NSCLC were tested simultaneously or sequentially with the cobas EGFR mutation test and ODxTT. We compared the success and detection rates of both tests and evaluated their equivalence by determining the concordance rate and k-coefficient of both tests.
RESULTS
The success rate in detecting EGFR mutations was 95.7% for ODxTT and 100% for cobas EGFR. EGFR mutations were detected in 26.5% of samples with ODxTT and in 28.0% with cobas EGFR. For the 200 samples successfully analyzed with both tests, the concordance rate and k-coefficient were 97.5% and 0.938, respectively. ODxTT failed to detect two exon 19 deletion mutations (p.E746_P753delinsVS and p.E746_P753delinsLS), and cobas EGFR failed to detect three instances of an exon 19 deletion (p.L747_P753delinsS), L861R, and an exon 20 insertion.
DISCUSSION
The success rate of ODxTT is slightly inferior to that of cobas EGFR. ODxTT shared a high concordance rate and k-coefficient with cobas EGFR in detecting EGFR mutations, but discordant results between the two tests were observed in a few cases, mainly due to the difference of detectable EGFR variants.
Identifiants
pubmed: 36203199
doi: 10.1111/1759-7714.14685
pmc: PMC9663664
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3217-3224Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Cancer Sci. 2020 Jul;111(7):2488-2498
pubmed: 32426898
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Thorac Cancer. 2022 Nov;13(22):3217-3224
pubmed: 36203199
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Sci. 2022 Jan;113(1):221-228
pubmed: 34704312
Clin Lung Cancer. 2019 Jan;20(1):20-29.e8
pubmed: 30243889
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
Lancet Respir Med. 2022 Jan;10(1):72-82
pubmed: 34454653
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Cancer Sci. 2019 Apr;110(4):1480-1490
pubmed: 30742731
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Ther Adv Med Oncol. 2020 Feb 22;12:1758835920904522
pubmed: 32127924
J Clin Oncol. 2013 Aug 10;31(23):2895-902
pubmed: 23835707
J Clin Oncol. 2009 Mar 20;27(9):1394-400
pubmed: 19224850
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Pathol Int. 2020 Dec;70(12):921-931
pubmed: 32956529
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Thorac Cancer. 2021 Jan;12(2):194-200
pubmed: 33185331
J Thorac Oncol. 2006 Mar;1(3):231-9
pubmed: 17409862
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
Diagnostics (Basel). 2021 Feb 25;11(3):
pubmed: 33668993
J Clin Oncol. 2020 Jan 10;38(2):115-123
pubmed: 31682542
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
pubmed: 15741570